JP2014097964A5 - - Google Patents

Download PDF

Info

Publication number
JP2014097964A5
JP2014097964A5 JP2012251831A JP2012251831A JP2014097964A5 JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5 JP 2012251831 A JP2012251831 A JP 2012251831A JP 2012251831 A JP2012251831 A JP 2012251831A JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012251831A
Other languages
English (en)
Japanese (ja)
Other versions
JP6146990B2 (ja
JP2014097964A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012251831A priority Critical patent/JP6146990B2/ja
Priority claimed from JP2012251831A external-priority patent/JP6146990B2/ja
Publication of JP2014097964A publication Critical patent/JP2014097964A/ja
Publication of JP2014097964A5 publication Critical patent/JP2014097964A5/ja
Application granted granted Critical
Publication of JP6146990B2 publication Critical patent/JP6146990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012251831A 2012-11-16 2012-11-16 重水素化されたcftr増強物質 Active JP6146990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017022718A Division JP2017105824A (ja) 2017-02-10 2017-02-10 重水素化されたcftr増強物質

Publications (3)

Publication Number Publication Date
JP2014097964A JP2014097964A (ja) 2014-05-29
JP2014097964A5 true JP2014097964A5 (enExample) 2016-01-07
JP6146990B2 JP6146990B2 (ja) 2017-06-14

Family

ID=50940312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012251831A Active JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Country Status (1)

Country Link
JP (1) JP6146990B2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2745977C2 (ru) 2010-04-22 2021-04-05 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
SG10201913575VA (en) 2014-04-15 2020-02-27 Vertex Pharma Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
IL310969A (en) * 2015-06-30 2024-04-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3476850B1 (en) * 2016-07-25 2024-12-11 Shenzhen TargetRx, Inc. Substituted boric acid compound, pharmaceutical composition comprising same, and application thereof
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
SG11202004264VA (en) * 2017-12-01 2020-06-29 Vertex Pharma Processes for making modulators of cystic fibrosis transmembrane conductance regulator
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド 重水素化されたcftr増強物質
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
HRP20040940A2 (en) * 2002-04-08 2005-04-30 Pfizer Inc. Tropane derivatives as ccr5 modulators
RU2331649C2 (ru) * 2002-06-20 2008-08-20 Ай-Си Ви-И-Си Лимитед Серосодержащие фосфолипидные производные, содержащая их фармацевтическая композиция, их применение для лечения заболеваний и способ их получения
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
PL2709986T3 (pl) * 2011-05-18 2017-09-29 Concert Pharmaceuticals Inc. Deuterowane pochodne iwakaftoru

Similar Documents

Publication Publication Date Title
JP2014097964A5 (enExample)
JP2014515351A5 (enExample)
JP2015528020A5 (enExample)
JP2018534348A5 (enExample)
JP2013537203A5 (enExample)
JP2015145426A5 (enExample)
JP2013032389A5 (enExample)
JP2015512931A5 (enExample)
JP2014500861A5 (enExample)
JP2015512432A5 (enExample)
JP2013542261A5 (enExample)
JP2011037841A5 (enExample)
JP2016500111A5 (enExample)
JP2013509429A5 (enExample)
JP2017537066A5 (enExample)
JP2010001302A5 (enExample)
JP2011518833A5 (enExample)
JP2013518107A5 (enExample)
JP2016529306A5 (enExample)
JP2016540749A5 (enExample)
JP2012519182A5 (enExample)
JP2012532883A5 (enExample)
JP2014503593A5 (enExample)
JP2013538857A5 (enExample)
JP2016534088A5 (enExample)